BI 1815368

Unknown / undisclosed

Phase 2Undisclosed / early pipeline
Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Diabetic Macular Edema
Phase 1 (6)
Other / comorbidity
NCT07693218 · Boehringer Ingelheim
2026-07-16 – 2026-09-04 · Healthy
What this study did
NCT06655220 · Boehringer Ingelheim
2024-11-08 – 2025-01-13 · Healthy
What this study did
NCT06494774 · Boehringer Ingelheim
2024-08-19 – 2024-11-13 · Healthy
What this study did
NCT05857878 · Boehringer Ingelheim
2023-06-23 – 2024-06-06 · Healthy
What this study did
NCT05965583 · Boehringer Ingelheim
2023-08-02 – 2023-10-24 · Healthy
What this study did
NCT05337592 · Boehringer Ingelheim
2022-06-14 – 2022-10-18 · Healthy
What this study did

Competitive landscape

This drug's own stage for Diabetic Macular Edema: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
BI 1815368: this drugPhase 2——not yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Eylea)ApprovedProtein / enzyme therapeuticVEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF)not yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Abzv (Enzeevu)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Ayyh (Pavblu)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Boav (Eydenzelt)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Jbvf (Yesafili)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Mrbb (Ahzantive)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Yszy (Opuviz)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Brolucizumab-DbllApprovedAntibody fragmentVEGF-APartial signalNo reviewed efficacy summary in this indication
FaricimabApprovedMultispecific antibodyAngiopoietin-2 / VEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Lucentis)ApprovedAntibody fragmentVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Eqrn (Cimerli)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Hkdz (Ranluspec)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Leyk (Nufymco)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
RC28-EPhase 3Protein / enzyme therapeuticVEGF-A / FGF-2 (dual blockade)Partial signal
NCT05885503: Primary endpoint, mean BCVA change at week 52: non-inferior to aflibercept 2.0 mg (316 subjects) (2025-09-30).
Tabirafusp TedromerPhase 3Multispecific antibodyVEGF + IL-6not yet gradedNo reviewed efficacy summary in this indication
MS-553Phase 1Small moleculeProtein kinase C-beta (PKC-beta)not yet gradedNo reviewed efficacy summary in this indication
MK-3000
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
RG6209
—(overall)
Antibody fragment—not yet gradedNo reviewed efficacy summary in this indication
RG6697
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
RG6913
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow BI 1815368 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
March 2028 (1)
Phase 2Diabetic Macular EdemaRecruiting
Est. primary completion 2028-03-01 · NCT06962839 · CT.gov ↗
What to watch

See the full readout calendar ↗